Histamine H2 receptor gene variants: Lack of association with schizophrenia

Molecular Psychiatry

Volumn 5, Issue 2, 2000, Pages 159-164

  Ito, C ^a   Morisset, S ^a   Krebs, M O ^b   Olie J P ^b   Loo H ^b   Poirier, M F ^b   Lannfelt, L ^c   Schwartz, J C ^a   Arrang, J M ^a,d  

^a U de Neurobiologie et Pharmacol M   (France)

^b CENTRE HOSPITALIER SAINTE ANNE   (France)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d CENTRE PAUL BROCA   (France)

Author keywords

Association study; Direct sequencing; Histamine H2 receptor; PCR; Polymorphism; Restriction endonuclease digestion; Schizophrenia

Indexed keywords

HISTAMINE H2 RECEPTOR; RESTRICTION ENDONUCLEASE;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENE EXPRESSION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SCHIZOPHRENIA; CAUCASIAN; CLINICAL TRIAL; COMPARATIVE STUDY; FRANCE; GENETICS; GENOTYPE; MULTICENTER STUDY; REFERENCE VALUE; SWEDEN; UNITED KINGDOM;

EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FRANCE; GENOTYPE; GREAT BRITAIN; HUMANS; MALE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RECEPTORS, HISTAMINE H2; REFERENCE VALUES; SCHIZOPHRENIA; SWEDEN; VARIATION (GENETICS);

EID: 0033625476     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000664     Document Type: Article

References (12)

1. 1 Schwartz J-C, Arrang J-M, Garbarg M, Traiffort E. Histamine. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York, 1995, pp 397-405.
2. 2 Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG et al. Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationship to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res 1995; 14: 93-104.
3. 2A receptor blockade. J Pharmacol Exp Ther 1999; 288: 590-596.
4. 1 receptors in the frontal cortex of brains from patients with chronic schizophrenia. Biol Psych 1991; 30: 349-356.
5. 5 Kaminsky R, Moriarty TM, Bodine J, Wolf DE, Davidson M. Effect of famotidine on deficit symptoms of schizophrenia. Lancet 1990; 335: 1351-1352.
6. 6 Oyewumi LK, Vollick D, Morskey H, Plumb C. Famotidine as an adjunctive treatment of resistant schizophrenia. J Psych Neurosci 1994; 19: 145-150.
7. 7 Rosse RB, Kondrick K, Fay-McCarthy M, Prell GD, Rosenberg P, Tsui LG et al. An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. Clin Neuropharmacol 1996; 19: 341-348.
8. 2 receptor gene. Neuroreport 1996; 7: 1293-1296.
9. 2 receptor gene. Mol Psychiatry 1996; 1: 466-469.
10. 10 Kunkel LM, Smith KD, Boyer SH, Borgaonkar DS, Wachtel SS, Miller OJ et al. Analysis of human Y chromosome specific reiterated DNA in chromosome variants. Proc Natl Acad Sci USA 1977; 74: 1245-1249.
11. 2 receptor. Biochem Biophys Res Commun 1991; 178: 1386-1392.
12. 2 receptor gene. Biorhem Biophys Res Commun 1995; 210: 616-623.